Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - idarubicin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - idarubicin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - idarubicin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - idarubicin hydrochloride, quantity: 1 mg/ml - injection, solution - excipient ingredients: glycerol; hydrochloric acid; water for injections - idamycin pfs injection in combination with other approved anti leukemic drugs is indicated for the treatment of acute myeloid leukemia (aml) in adults. this includes the french-american-british (fab) classifications m1 through m7.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - idarubicin hydrochloride, quantity: 1 mg/ml - injection, solution - excipient ingredients: glycerol; hydrochloric acid; water for injections - idamycin pfs injection in combination with other approved anti leukemic drugs is indicated for the treatment of acute myeloid leukemia (aml) in adults. this includes the french-american-british (fab) classifications m1 through m7.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - idarubicin hydrochloride, quantity: 1 mg/ml - injection, solution - excipient ingredients: glycerol; hydrochloric acid; water for injections - idamycin pfs injection in combination with other approved anti leukemic drugs is indicated for the treatment of acute myeloid leukemia (aml) in adults. this includes the french-american-british (fab) classifications m1 through m7.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - idarubicin hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - idarubicin hydrochloride 10mg; idarubicin hydrochloride 10mg; idarubicin hydrochloride 10mg - capsule - 10 mg - active: idarubicin hydrochloride 10mg excipient: gelatin glyceryl palmito-stearate iron oxide red microcrystalline cellulose opacode black s-1-27794 titanium dioxide active: idarubicin hydrochloride 10mg excipient: gelatin glyceryl palmito-stearate iron oxide red microcrystalline cellulose titanium dioxide active: idarubicin hydrochloride 10mg excipient: gelatin glyceryl palmito-stearate iron oxide red microcrystalline cellulose tekprint black sw-9008 titanium dioxide - zavedos is an antimitotic and cytotoxic agent. it is indicated for use in acute myelogenous leukaemia (aml), in adults for remission induction in untreated patients, or for remission induction in relapsed or refractory patients. zavedos capsules are indicated whenever the intravenous route is not considered suitable. zavedos is also an effective agent for use in the second line treatment of advanced breast cancer either as a single agent or in a combination regimen.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - idarubicin hydrochloride 25mg; idarubicin hydrochloride 25mg; idarubicin hydrochloride 25mg - capsule - 25 mg - active: idarubicin hydrochloride 25mg excipient: gelatin glyceryl palmito-stearate microcrystalline cellulose opacode black s-1-27794 titanium dioxide active: idarubicin hydrochloride 25mg excipient: gelatin glyceryl palmito-stearate microcrystalline cellulose titanium dioxide active: idarubicin hydrochloride 25mg excipient: gelatin glyceryl palmito-stearate microcrystalline cellulose tekprint black sw-9008 titanium dioxide - zavedos is an antimitotic and cytotoxic agent. it is indicated for use in acute myelogenous leukaemia (aml), in adults for remission induction in untreated patients, or for remission induction in relapsed or refractory patients. zavedos capsules are indicated whenever the intravenous route is not considered suitable. zavedos is also an effective agent for use in the second line treatment of advanced breast cancer either as a single agent or in a combination regimen.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - idarubicin hydrochloride 5mg; idarubicin hydrochloride 5mg; idarubicin hydrochloride 5mg - capsule - 5 mg - active: idarubicin hydrochloride 5mg excipient: gelatin glyceryl palmito-stearate iron oxide red microcrystalline cellulose opacode black s-1-27794 titanium dioxide active: idarubicin hydrochloride 5mg excipient: gelatin glyceryl palmito-stearate iron oxide red microcrystalline cellulose titanium dioxide active: idarubicin hydrochloride 5mg excipient: gelatin glyceryl palmito-stearate iron oxide red microcrystalline cellulose tekprint black sw-9008 titanium dioxide - zavedos is an antimitotic and cytotoxic agent. it is indicated for use in acute myelogenous leukaemia (aml), in adults for remission induction in untreated patients, or for remission induction in relapsed or refractory patients. zavedos capsules are indicated whenever the intravenous route is not considered suitable. zavedos is also an effective agent for use in the second line treatment of advanced breast cancer either as a single agent or in a combination regimen.